Transcranial Magnetic Stimulation (TMS) Treatment for Alcohol Use Disorder
Launched by NASSIMA AIT-DAOUD TIOURIRINE · May 28, 2019
Trial Information
Current as of May 22, 2025
Unknown status
Keywords
ClinConnect Summary
This is a randomized double- blind, control study.
To test the hypothesis, the investigator propose a 2 phase design:
Phase 1: 6-week trial comparing the efficacy of active high-frequency (HF) rTMS of L-DLPFC versus sham (SS) rTMS to determine if HF rTMS improves cognitive flexibility in recently detoxified alcoholics Phase 2: at the end of TMS phase, all participants will receive cognitive behavioral therapy (CBT) thus permitting participants with AUD to benefit from cognitive restructuring in CBT, and reduce alcohol cravings and drinking outcomes.
This study will recruit 20 individuals...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Right handed males and females who have given written informed consent.
- • Age 22 years and above with a history of alcohol use disorder
- • Good physical health
- • Have a current diagnosis of alcohol use disorder
- • Reports at least 4 "heavy drinking days" on average in the past 30 days.
- • Have a BAC by breathalyzer equal to 0.000 when the participants signed the informed consent document
- • Six months stability on any psychotropic medications
- • Not have any unresolved legal problems that could jeopardize continuation or completion of the study.
- • Be able to provide written informed consent, able to understand written and oral instructions in English and be able to complete the questionnaires required by the protocol.
- Exclusion Criteria:
- • Please contact site for additional information.
About Nassima Ait Daoud Tiouririne
Nassima Ait-Daoud Tiouririne is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative study design and rigorous trial management. With a commitment to ethical practices and regulatory compliance, Nassima leads initiatives that explore new therapeutic options across various medical fields. Her expertise in clinical operations and strategic collaborations fosters an environment of excellence, ensuring that all trials not only adhere to the highest standards of scientific integrity but also prioritize participant safety and well-being. Through her leadership, Nassima Ait-Daoud Tiouririne aims to bridge the gap between research and real-world applications, contributing to the evolution of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlottesville, Virginia, United States
Patients applied
Trial Officials
Nassima Ait-Daoud TIouririne, M.D.
Principal Investigator
University of Virginia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials